It's been a good week for BioNTech SE (NASDAQ:BNTX) shareholders, because the company has just released its latest quarterly results, and the shares gained 3.6% to US$111. It was a moderately negative ...

CureVac and GSK will receive $740 million and single-digit royalties on COVID-19 vaccine sales in the U.S. going forward.

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac $740 million plus royalties to settle US legal disputes over Covid-19 vaccines, ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...

GSK said the upfront settlement amount will be recorded as other operating income in its financial results as an adjusting item in the income statement in the third quarter of 2025. The 2025 and ...

GSK said it would receive $370 million as part of a U.S. patent settlement between CureVac and BioNTech related to messenger mRNA-based Covid-19 vaccines.

In early corporate news, GSK wins a payout after settlement is reached in the legal action between partner CureVac and BioNTech on Thursday, while Renewables Infrastructure posts a widened interim ...

The Cancer Vaccine Launch Pad – a partnership between NHS England, the Government and BioNTech – has already helped refer ...

The vaccine used in this trial, known as AHEAD-MERIT (BNT113-01), will help the immune system recognise and kill cancer cells ...

(Reuters) -CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with ...

German drugmaker CureVac and GSK reached an agreement with BioNTech and Pfizer on Thursday to resolve a years-long patent ...